Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2016 Jun;16(2):462-7.
doi: 10.4314/ahs.v16i2.14.

Levels of vitamin D receptor and CYP24A1 in patients with end-stage renal disease

Jia-Jun Ye  1 , Tian-Biao Zhou  2 , Yun-Fang Zhang  1 , Qi Wang  1 , Yan-Yan Su  1 , Jia-Min Tang  1 , Hong-Yan Li  1
Affiliations
Comparative Study

Levels of vitamin D receptor and CYP24A1 in patients with end-stage renal disease

Jia-Jun Ye et al. Afr Health Sci. 2016 Jun.

Abstract

Objective: This study was performed to detect the expression of vitamin D receptor (VDR) and cytochrome P450, family 24, subfamily A, polypeptide 1 (CYP24A1) in 24 end stage renal disease (ESRD) patients and 24 healthy controls.

Method: In this study, 24 ESRD patients and 24 healthy controls were included.

Results: In our study, the levels of VDR in patients with ESRD were reduced when compared with those from healthy controls (5.20±0.32 vs 8.59±1.03; P<0.01). However, the levels of CYP24A1 in ESRD patients were increased than those from healthy controls (50.18±21 vs 7.78±1.31; P<0.01). Correlation analysis showed that VDR levels were negatively correlated with CYP24A1 (r=-0.723; P<0.01).

Conclusion: VDR levels were reduced and CYP24A1 levels were increased in patients with ESRD, and VDR levels were negatively correlated with CYP24A1.

Keywords: CYP24A1; Vitamin D receptor (VDR); end-stage renal disease (ESRD).

PubMed Disclaimer

Figures

Figure 1
Figure 1
VDR levels in two groups. *: when compared with ESRD group, P<0.01
Figure 2
Figure 2
CYP24A1 levels in two groups. *: when compared with ESRD group, P<0.01
See this image and copyright information in PMC

References

    1. Zhou TB, Yin SS, Qin YH. Association between angiotensin-converting enzyme insertion/deletion gene polymorphism and end-stage renal disease susceptibility. J Renin Angiotensin Aldosterone Syst. 2014;15(1):22–31. - PubMed
    1. Zhou TB, Yin SS, Qin YH. Association of angiotensinogen M235T gene polymorphism with end-stage renal disease risk: a meta-analysis. Mol Biol Rep. 2013;40(2):765–772. - PubMed
    1. Zhang YF, Zhou TB, Jiang ZP, Li HY. Association of vitamin D receptor BsmI (rs1544410) gene polymorphism with the intact parathyroid hormone (iPTH) level among patients with end-stage renal disease. J Recept Signal Transduct Res. 2015;35(2):133–136. - PubMed
    1. Bover J, Lloret MJ, DaSilva I, Furlano M, Diaz M, Herreros A, et al. Role of vitamin D receptor activators in peritoneal dialysis. Contrib Nephrol. 2012;178:124–142. - PubMed
    1. Pulito C, Terrenato I, Di Benedetto A, Korita E, Goeman F, Sacconi A, et al. Cdx2 polymorphism affects the activities of vitamin D receptor in human breast cancer cell lines and human breast carcinomas. PLoS One. 2015;10(4):e0124894. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources